Healthcare Tech Firm and Leading University to Join Forces

1. Treatment.com AI Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI Inc.
3. Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor.
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) and Scotland's University of Edinburgh signed an agreement to jointly build applications, backed by Treatment's proprietary Global Library of Medicine (GLM), as part of a multimillion-dollar university program to optimize long-term patient care, a news release noted.

The program, called SET4, or Systems Engineering to Transform Transitions In Health and Social Care, entails developing innovative, data-driven solutions to problematic transitions in health and social care for people living with multiple long-term medical conditions. The Usher Institute, part of the university's College of Medicine and Veterinary Medicine, is heading the effort.

While the goal of SET4 is initially to make changes to improve specific communities in Scotland, the vision is to take any learnings to "deliver meaningful change with sufficient evidence to enable wider adoption across the United Kingdom National Health Service, other social care settings and beyond," noted the release.

Julie Jacko, the College of Medicine and Veterinary Medicine's Dean of Innovation and Engagement, said, "Our partnership with Treatment.com AI will amplify the impact of our work, ensuring that health and well-being is improved for generations to come."

In other announced news, Treatment amended its marketing and investor relations agreement with LEIT Media Ltd. Treatment will pay LEIT €250,000 for the current marketing campaign targeting the German-speaking investor community.

Improving Healthcare

The mission of Treatment.com AI, headquartered in Vancouver, British Columbia, is to transform and improve healthcare by developing and providing software that combines artificial intelligence (AI) and best clinical practices to assist providers and eradicate inefficiencies.

The foundation of the company's solutions is its very own digital platform, the GLM, developed using in-house algorithms and input from hundreds of healthcare professionals around the world. According to Treatment, it is "one of the most comprehensive and accurate repositories of curated diagnostic medical information currently in the world."

With the GLM, combined with the artificial intelligence (AI) healthcare market projecting to grow from $11 billion today to $187 billion in 2030, Treatment has significant growth potential, the company noted on its website.

"The opportunities available to expand the use of our GLM platform to help solve many of the challenges facing the broader medical industry are diverse and long-term," Treatment said.

Currently, the healthcare tech company is extending its portfolio and has announced several new developments scheduled for the latter part of 2024.

Supporting physicians, nurses, and pharmacists, the "comprehensive, personalized healthcare AI engine" that is the GLM provides case-specific clinical assessments, information, and recommendations, the company said. The GLM suggests “most likely” diagnoses, with a 92% plus accuracy, most appropriate physical and lab tests and x-rays, and, if needed, associated billing codes.

"The most important aspect underpinning future clinical decision support is the quality and trustworthiness of medical information," Dr. Essam Hamza, Treatment's Chief Executive Officer and director, said on the company website.

A "comprehensive, personalized healthcare AI engine" is how Treatment describes the GLM, resulting in improved patient outcomes, affording providers more quality time with patients, lower administration time and costs for healthcare professionals and systems, helping mitigate fraud within healthcare systems, and contributing to resolving health inequity.

"The GLM provides the highest level of qualified clinical and support to all health care professionals, ensuring enhanced diagnostic accuracy and transparency in every step of support provided," Technical Analyst Clive Maund wrote in a July report.

Treatment's next offering, also supported by the GLM, is for pharmacists, noted Streetwise Reports. Called AI Pharmacy Assistant, the software is slated for release later this year.

Treatment also focuses on the next generation of healthcare professionals with its software packages for medical and nursing school educators and students. Utilizing the GLM, the Medical Education Suite helps strengthen students' practical clinical skills.  

Market Having Growth Spurt

AI in healthcare, according to Fortune Business Insights, is used to analyze the medical data that helps medical providers make accurate diagnoses and accurate treatment to their patients. AI in healthcare assists physicians, nurses and other healthcare workers enhance their productivity.

The value of the global AI in healthcare market is projected to reach US$490.96 billion (US$490.96B) by 2032 from US$19.54B in 2023. This reflects a compound annual growth rate of 43.2%.

The platform segment is expected to lead the market during this period.

Drivers of current and future overall growth of AI in the healthcare market are many. Fortune points to private and government investments in the sector and advancements in medicine, research, innovation and technology,

According to Data Bridge Market Research, the adoption of AI and machine learning technologies and innovative product development are spurring overall growth.

Market and Markets attributes the growth to "the generation of large and complex healthcare data sets, the pressing need to reduce healthcare costs, improving computing power and declining hardware costs, the rising number of partnerships and collaborations among different domains in the healthcare sector, and the growing need for improvised healthcare services due to imbalance between healthcare workforce and patients."

In terms of geography, North America dominated the global AI market in the healthcare industry last year with a 44.93% share, noted Fortune. This is in part because of its strong base of healthcare facilities, high adoption rate of minimally invasive procedures, and high healthcare spending, according to Data Bridge. Other contributors are an expanding elderly population, rising investment in advanced devices, and increasing research activities.

The Catalyst: Further Opportunities

The recent agreement is a catalyst for Treatment and the University of Edinburgh to work together on additional innovative and commercial projects and programs aimed at improving healthcare efficiency and delivery through AI, the release noted.

"We are delighted and proud to work with Edinburgh Innovations to discover new ways of improving the lives of people initially in Scotland and subsequently across the world," Dr. Kevin Peterson, Treatment's founder, chief medical officer and chairman, said in the release.

Analyst: Stock Remains a Buy

Technical Analyst Maund reiterated his Buy rating on Treatment.com in a July report. He purported the stock has "great growth potential" and indicated he would stay long on it.

At that time, he also highlighted the waste and efficiencies in healthcare and the power of AI to change it.

"The potential for AI to improve the efficiency and quality of life for all involved is immense," he wrote. 

Earlier this year, Maund emphasized how well positioned in the sector Treatment is.

"The growth potential of this industry is enormous," he wrote. "With Treatment.com AI having already developed its own platform, it is centrally placed to be a part of this."

Ownership and Share Structure

According to Sedi.ca, insiders own 7.9% of Treatment.com AI.

Retail investors own the remaining 92%. 

As of September 6, 2024, Treatment has 48.29M outstanding common shares and 41,153,790 free float traded shares.

As of September 6, 2024, the market cap is CA$38.63M. Over the past 52 weeks, the company traded between CA$0.75 and CA$1.11 per share.